Studies showed reductions in the expression levels of FHIT have occurred in many kinds of malignancies, such as lung cancer [14], oropharyngeal squamous cell carcinomas [15], renal cell carcinomas [16] and colorectal carcinomas [17]. This evidence concerns the gene FHIT and lung carcinoma.